FindTrial
Sign In

Comparison of 2 drug combination with a 3 drug combination in patients with COPD

Comparison of Formeterol Budesonide formulation nebulized alone and in combinated with ipratropium bromide in patients with COPD

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/09/009901
Enrollment
100
Registered
2017-09-25
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Chronic Obstructive Pulmonary Disease

Interventions

Intervention1: Formeterol budesonide combination with ipratropim bromide: dis z just to see additional benefits dose -Formeterol (20 mcg) - Budesonide (1 mg) and then with Saline (2 ml) n ipratropium

Sponsors

Dr Juhi Singla
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. coming to Pulmonary medicine OPD 2. admitted in Pulmonary med Ward

Exclusion criteria

Exclusion criteria: 1. Cardiac Disease 2. Pregnancy 3. Diabetes mellitus 4. Malignancy

Design outcomes

Primary

MeasureTime frame
efficacy and tolerability of formeterol-budesonide formulation nebulized alone and with ipratropium bromideTimepoint: 30 mins after nebulization—

Secondary

MeasureTime frame
Electrolyte imbalances n electrocardiograhic changesTimepoint: 30 minutes—

Countries

India

Contacts

Public ContactJuhi Singla

FMHS, SGT University, Gurgaon

sccpharma@gmail.com8800338751

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026